Przegaliński E, Budziszewska B, Grochmal A
Institute of Pharmacology, Polish Academy of Sciences, Kraków.
Acta Endocrinol (Copenh). 1992 Nov;127(5):471-5. doi: 10.1530/acta.0.1270471.
In this study we examined the effect of the adenosine analogues: N6-cyclohexyladenosine, L-N6-phenylisopropyladenosine and 5'-N-ethylcarboxamidoadenosine on the plasma corticosterone concentration in rats. It was found that N6-cyclohexyladenosine (0.1-3.0 mg/kg), L-N6-phenylisopropyladenosine (0.1-1.0 mg/kg) and 5'-N-ethylcarboxamidoadenosine (0.01-1.0 mg/kg) dose-dependently increased the plasma corticosterone level. The effects of N6-cyclohexyladenosine (0.1 mg/kg) and L-N6-phenylisopropyladenosine (0.1 mg/kg) were completely blocked in animals pretreated with dexamethasone (3 x 1 mg/kg), as well as in animals with a pharmacological blockade of the release of hypothalamic corticotropin-releasing factor induced by chloropromazine (10 mg/kg), morphine (20 mg/kg) and nembutal (25 mg/kg), whereas the corticosterone response to 5'-N-ethylcarboxamidoadenosine (0.01 mg/kg) was blocked in dexamethasone-pretreated rats only. On the other hand, the adenosine receptor antagonists: 8-(p-sulfophenyl)-theophylline (30 mg/kg), 8-phenyltheophylline (10 and 30 mg/kg), 1,3-dipropyl-8-(2-amino-4-chloro)-phenylxanthine (1 and 3 mg/kg) and 1,3-dipropyl-7-methylxanthine (1 mg/kg) did not affect the corticosterone response to N6-cyclohexyladenosine, L-N6-phenylisopropyladenosine or 5'-N-ethylcarboxamidoadenosine. The obtained results indicate that N6-cyclohexyladenosine and L-N6-phenylisopropyladenosine stimulate the corticosterone secretion at the hypothalamic level, whereas 5'-N-ethylcarboxamidoadenosine is likely to act at the pituitary level. Although the effects produced by the adenosine analogues show that both A1 and A2 receptors are involved in the corticosterone response, negative results of the interaction studies with adenosine receptor antagonists indicate that further experiments are necessary to elucidate this problem.
在本研究中,我们检测了腺苷类似物:N6 - 环己基腺苷、L - N6 - 苯基异丙基腺苷和5'-N - 乙基羧酰胺腺苷对大鼠血浆皮质酮浓度的影响。结果发现,N6 - 环己基腺苷(0.1 - 3.0毫克/千克)、L - N6 - 苯基异丙基腺苷(0.1 - 1.0毫克/千克)和5'-N - 乙基羧酰胺腺苷(0.01 - 1.0毫克/千克)可剂量依赖性地提高血浆皮质酮水平。N6 - 环己基腺苷(0.1毫克/千克)和L - N6 - 苯基异丙基腺苷(0.1毫克/千克)的作用在预先用地塞米松(3×1毫克/千克)处理的动物中完全被阻断,在通过氯丙嗪(10毫克/千克)、吗啡(20毫克/千克)和戊巴比妥(25毫克/千克)诱导下丘脑促肾上腺皮质激素释放因子释放被药理阻断的动物中也完全被阻断,而对5'-N - 乙基羧酰胺腺苷(0.01毫克/千克)的皮质酮反应仅在预先用地塞米松处理的大鼠中被阻断。另一方面,腺苷受体拮抗剂:8 - (对 - 磺基苯基) - 茶碱(30毫克/千克)、8 - 苯基茶碱(10和30毫克/千克)、1,3 - 二丙基 - 8 - (2 - 氨基 - 4 - 氯) - 苯基黄嘌呤(1和3毫克/千克)和1,3 - 二丙基 - 7 - 甲基黄嘌呤(1毫克/千克)不影响对N6 - 环己基腺苷、L - N6 - 苯基异丙基腺苷或5'-N - 乙基羧酰胺腺苷的皮质酮反应。所得结果表明,N6 - 环己基腺苷和L - N6 - 苯基异丙基腺苷在下丘脑水平刺激皮质酮分泌,而5'-N - 乙基羧酰胺腺苷可能作用于垂体水平。尽管腺苷类似物产生的作用表明A1和A2受体都参与了皮质酮反应,但与腺苷受体拮抗剂相互作用研究的阴性结果表明,需要进一步实验来阐明这个问题。